Exparel 133 MG/10 ML vial 10ML
Ended Awarded
- Contract number
- SPE2DB25FDM20
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,277
Award facts
- Contract value 100% obligated
- $18,276.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $18,276.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Exparel (liposomal bupivacaine) 133 mg/10 mL vials. The contract is a firm fixed-price delivery order with an ultimate completion date of October 16, 2025, and was awarded on September 24, 2025. This award carries no set-aside designation, demonstrating the vendor's competitive strength in the federal pharmaceutical procurement marketplace.
This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide. As a critical supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group regularly delivers branded and generic prescription drugs, biologics, and medical consumables to military health facilities. Exparel, a long-acting local anesthetic, is a specialized pharmaceutical product that aligns with the company's established portfolio of injectable medications and surgical pharmaceuticals supplied to federal healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FDM20?
SPE2DB25FDM20 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 24, 2025.
How much is contract SPE2DB25FDM20 worth?
The government has obligated $18,277 on SPE2DB25FDM20.
Is contract SPE2DB25FDM20 an order under another contract?
Yes. SPE2DB25FDM20 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDM20 competed?
The extent of competition for SPE2DB25FDM20 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award